Costs and risks in the management of patients with gastric acid hypersecretion

Journal of Clinical Gastroenterology

Volumn 44, Issue 1, 2010, Pages 28-33

  Hirschowitz, Basil I ^a   Fineberg, Naomi ^b   Wilcox, C Mel ^a   Mohnen, Jean ^a   Worthington, Julie ^a  

^a Division of Gastroenterology and Hepatology   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Gastric analysis; Lansoprazole; Medical cost; Proton pump inhibitor; Zollinger Ellison syndrome

Indexed keywords

LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAGASTRIN;

ADULT; ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GASTROSCOPY; HEALTH CARE COST; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RISK FACTOR; STOMACH ACID; STOMACH ACID SECRETION; STOMACH ANTRUM RESECTION; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; COSTS AND COST ANALYSIS; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; YOUNG ADULT; ZOLLINGER-ELLISON SYNDROME;

EID: 75149178746     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181a59aa5     Document Type: Article

References (15)

1. Hirschowitz BI, Simmons J, Mohnen J. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non- ZE hypersecretors: a prospective 10-year study. Aliment Pharmacol Ther. 2001;15:1795-1806.
2. Pisegna JR, Norton JA, Slimak GG, et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology. 1992;102:767-778.
3. Metz DC, Benya RV, Fishbeyn VA, et al. Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection. Aliment Pharmacol Ther. 1993;7:247-257.
4. Metz DDG, Pisegna JK, Fushbein VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992;103:1498-1508.
5. Jensen RT. Consequences of long-term proton pump blockade: insight from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4-19.
6. Hirschowitz BI, Haber MM. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger- Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Pharmacol Ther. 2001;15:87-103.
7. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger- Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol. 2005;3:39-48.
8. Hirschowitz BI, Groarke J. Vagal effects on acid and pepsin secretion and serum gastrin in duodenal ulcer and controls. Dig Dis Sci. 1993;38:1874-1884.
9. Hirschowitz BI. Normal function of stomach. In: Graham DY, ed. Gastritis. Philadelphia: Lippincott-Raven Publishers; 1999:9-31.
10. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol. 1999;17:615-630.
11. Hirschowitz BI. Clinical course of non-surgically treated Zollinger-Ellison Syndrome. In Series "Frontiers of Gastrointestinal Research," S. Karger AG, Basel. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas-Recent Advances in Research and Management. 1995:360-371.
12. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton-pump inhibitors. Aliment Pharmacol Ther. 2008;27:1110-1121.
13. Hirschowitz BI, Simmons J, Johnson L, et al. Risk factors for esophagitis in extreme acid hypersecretors with and without Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol. 2004;2:220-229.
14. Penston JG, Wormley KG. Review article: asymptomatic duodenal ulcers-implications of heterogeneity. Aliment Pharmacol Ther. 1990;4:557-567.
15. Miner P. Review article: relief of symptoms in gastric acidrelated disease correlation with acid suppression in rabeprazole treatment. Aliment Pharmacol Ther. 2004;20:20-29.